ARS Pharmaceuticals Inc (SPRY) Stock News

A securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about expected July 1, 2026 coverage, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

Schall, Brown & Schwartz LLP announced a securities fraud class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for making false and misleading statements regarding timeline issues related to CVS Caremark's addition of neffy to its formulary. The class period spans March 9, 2026 to June 24, 2026, with an October 5, 2026 deadline for investors to participate. Shareholders who suffered losses are encouraged to contact the firm regarding lead plaintiff appointments.

Rosen Law Firm announces class action securities lawsuits against ARS Pharmaceuticals (SPRY) and Datavault AI (DVLT), with October 5, 2026 deadline for investors to join. ARS Pharmaceuticals is accused of providing misleading statements regarding insurance coverage expansion timeline for its epinephrine spray product neffy through CVS Caremark, allegedly causing investors to purchase shares at artificially inflated prices.

Pomerantz Law Firm has filed a class action lawsuit against ARS Pharmaceuticals (NASDAQ: SPRY) alleging securities fraud. The lawsuit was triggered after ARS announced on June 24, 2026, that it failed to secure expanded insurance coverage for its epinephrine nasal spray product 'neffy' through CVS Caremark by the July 1 deadline. The announcement caused ARS's stock to plummet 23.91% to $8.02 per share on June 25, 2026. Investors have until October 5, 2026, to request appointment as Lead Plaintiff.

A securities class action lawsuit has been filed against ARS Pharmaceuticals (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about a July 1, 2026 coverage start date, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing misleading statements to investors regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company reportedly made confident statements about July 1, 2026 coverage while concealing material adverse facts, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

Pomerantz Law Firm has filed class action lawsuits against ARS Pharmaceuticals, Inc. and other companies for alleged securities fraud. ARS's stock fell 23.91% after the company failed to secure expanded insurance coverage for its epinephrine nasal spray (neffy) through CVS Caremark by the July 1, 2026 deadline. Investors have until October 5, 2026 to join the class action.

Holzer & Holzer, LLC announces lead plaintiff deadlines for shareholder class action lawsuits against three companies: Pentair plc for alleged false statements regarding inventory destocking in its Pool channel (deadline October 2, 2026); Datavault AI Inc. for alleged misrepresentations about partnership value and trading activity (deadline October 5, 2026); and ARS Pharmaceuticals, Inc. for alleged false statements about insurance coverage timeline for its epinephrine nasal spray product (deadline October 5, 2026).

Schall, Brown & Schwartz LLP announced a securities fraud class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for making false and misleading statements regarding timeline issues related to CVS Caremark's addition of neffy to its formulary. The class period spans March 9, 2026 to June 24, 2026, with a deadline of October 5, 2026 for investors to participate. The lawsuit alleges the company recklessly disregarded risks that could significantly impact insurance coverage guidance and commercialization of neffy.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) alleging that defendants made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be eligible for compensation. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is urging investors in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) who purchased securities between March 9, 2026 and June 24, 2026 to join a class action lawsuit. The lawsuit alleges that company defendants made false and misleading statements regarding the expected timeline for CVS Caremark insurance coverage expansion for the company's epinephrine spray product, neffy, causing investors to purchase shares at artificially inflated prices. The deadline to file is October 5, 2026.

Rosen Law Firm is encouraging investors who purchased securities of ARS Pharmaceuticals (SPRY) between March 9, 2026 and June 24, 2026 to join a class action lawsuit. The firm alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product (neffy) through CVS Caremark, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is notifying investors of ARS Pharmaceuticals (SPRY) about a securities class action lawsuit with an October 5, 2026 lead plaintiff deadline. The lawsuit alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray 'neffy' through CVS Caremark, causing investors to purchase securities at artificially inflated prices.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) alleging that defendants made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be entitled to compensation. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding insurance coverage timelines for its epinephrine nasal spray product 'neffy' with CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be eligible for compensation. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is reminding investors who purchased ARS Pharmaceuticals securities between March 9, 2026 and June 24, 2026 of an October 5, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals provided false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product (neffy) through CVS Caremark, causing investors to purchase securities at artificially inflated prices.

A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product neffy through CVS Caremark. The company failed to disclose risks that the July 1, 2026 coverage deadline might not be met. When the truth emerged on June 24, 2026, ARS stock declined over 23.9% in a single day.